Shots:

• The company discontinues P-II proof POC study of Lu AF11167 in patients with schizophrenia- who are experiencing persistent negative symptoms (NCT03793712). The P-II study evaluated two doses of Lu AF11167 vs PBO as monothx. in patients with schizophrenia and persistent prominent negative symptoms
• The discontinuation is based on the results of a futility interim analysis- which concluded that trial fails to achieve 1EPs i.e. change from baseline to 12wk on BNSS. The recommendation to halt the trial is not based on safety concerns
• Lu AF11167 is a potent PDE10Ai inhibitor- modulating dopamine D1 and D2 receptor-mediated intraneuronal signaling without binding to these receptors. The company plans to randomize 240 patients from EU countries

Click here ­to­ read full press release/ article | Ref: Lundbeck | Image: Lundbeck